ROIX: AI 评分 46/100 — AI 分析 (4月 2026)

Response Oncology, Inc. is a company that formerly operated as a comprehensive cancer management company. The company liquidated substantially all of its operating assets in 2002 and anticipates completing all wind-down activities.

Key Facts: AI Score: 46/100 Sector: Healthcare

公司概况

概要：

Response Oncology, Inc., incorporated in 1984, previously offered advanced cancer treatment services, managed oncology practices, and compounded pharmaceuticals. Following the liquidation of its operating assets in 2002, the company has ceased significant operations and is based in Memphis, Tennessee.

ROIX是做什么的？

Response Oncology, Inc., established in 1984 and based in Memphis, Tennessee, once operated as a comprehensive cancer management company. The company, along with its subsidiaries, provided advanced cancer treatment services through outpatient facilities known as IMPACT Centers, under the direction of practicing oncologists. Additionally, Response Oncology owned the assets of and managed the non-medical aspects of oncology practices. The company also compounded and dispensed pharmaceuticals to certain oncologists for a fixed or cost-plus fee. Furthermore, Response Oncology conducted outcomes research on behalf of pharmaceutical manufacturers. However, as of May 20, 2002, the company liquidated substantially all of its operating assets. It anticipated that the remaining assets would be liquidated and all wind-down activities completed by the end of 2002, effectively ceasing its primary business operations. Currently, Response Oncology, Inc. does not have significant operations.

ROIX的投资论点是什么？

Response Oncology, Inc. presents a unique case for investors, given its historical context and current state. The company liquidated its operating assets in 2002 and has no significant operations as of 2026. With a market capitalization of $0.00B and a beta of -19.14, the stock's behavior may not align with typical market dynamics. Potential investors should carefully consider the implications of the company's dormant operational status and the absence of revenue-generating activities. Any investment decision should be based on a thorough understanding of the company's historical filings and any potential future plans, if disclosed.

ROIX在哪个行业运营？

Response Oncology, Inc. formerly operated within the medical care facilities industry, which involves providing services such as cancer treatment through outpatient facilities. The industry is characterized by technological advancements in treatment methods, evolving regulatory landscapes, and a focus on patient care. However, given that Response Oncology liquidated its assets in 2002, its current relevance to the industry is limited. Competitors in this space include companies like GNRS, LHRP, QMED, RFCS, and SYNI, which continue to operate and innovate within the healthcare sector.

Medical - Care Facilities

Healthcare

ROIX有哪些增长机遇？

Growth opportunity 1: Given that Response Oncology, Inc. has liquidated its operating assets and has no significant operations, traditional growth opportunities are not applicable. Any potential future growth would depend on a complete restructuring and a new business plan, which is not currently evident. The company would need to identify a new market, develop a viable business model, and secure funding to pursue any growth initiatives. This would essentially be a new venture under the same corporate shell.
Growth opportunity 2: The company could explore opportunities in healthcare technology, leveraging any remaining intellectual property or expertise from its past operations. This would require significant investment in research and development, as well as a deep understanding of current market needs and technological trends. The market for healthcare technology is projected to reach $280 billion by 2028, presenting a substantial opportunity for a company with the right strategy and resources.
Growth opportunity 3: Response Oncology could potentially re-enter the oncology care market by focusing on niche areas such as personalized medicine or telemedicine. This would require a strategic shift towards innovation and a focus on delivering specialized services to a targeted patient population. The personalized medicine market is expected to grow to $4.2 billion by 2027, offering a potential avenue for growth.
Growth opportunity 4: The company could consider acquiring or merging with another healthcare company to gain access to new markets, technologies, or expertise. This would require careful due diligence and a clear understanding of the strategic fit between the two organizations. The healthcare industry is undergoing consolidation, with numerous mergers and acquisitions occurring each year, presenting opportunities for companies to expand their reach and capabilities.
Growth opportunity 5: Response Oncology could explore opportunities in the development of new cancer therapies or diagnostic tools. This would require significant investment in research and development, as well as a strong understanding of the regulatory landscape and the clinical trial process. The market for cancer therapies is projected to reach $200 billion by 2027, offering a substantial opportunity for companies that can develop innovative treatments.

Market Cap: $0.00B indicates the company has negligible market capitalization.
Beta: -19.14 suggests the stock price moves inversely to the market, but this may not be reliable given the lack of operations.
Liquidation of assets completed in 2002, marking a significant shift in the company's business model.
No significant operations as of 2026, indicating a dormant business state.
Employee count of 10 suggests minimal ongoing business activity.

ROIX提供哪些产品和服务？

Formerly provided advanced cancer treatment services through outpatient facilities.
Managed the non-medical aspects of oncology practices.
Compounded and dispensed pharmaceuticals to oncologists.
Conducted outcomes research for pharmaceutical manufacturers.
Operated IMPACT Centers under the direction of practicing oncologists.
Liquidated substantially all operating assets as of May 20, 2002.
Currently has no significant operations.

ROIX如何赚钱？

Historically, Response Oncology generated revenue through cancer treatment services.
Revenue was also derived from managing oncology practices.
Pharmaceutical compounding and dispensing contributed to revenue streams.
Outcomes research conducted for pharmaceutical manufacturers provided additional income.

Practicing oncologists who directed IMPACT Centers.
Patients receiving cancer treatment services.
Pharmaceutical manufacturers seeking outcomes research.
Oncology practices for which Response Oncology managed non-medical aspects.

Historically, the company's network of IMPACT Centers provided a degree of geographic advantage.
Relationships with practicing oncologists offered a competitive edge in patient referrals.
In-house pharmaceutical compounding provided cost control and supply chain advantages.
Outcomes research capabilities differentiated the company in the pharmaceutical market.

什么因素可能推动ROIX股价上涨？

Ongoing: Potential for restructuring or acquisition by another company.
Ongoing: Any future announcements regarding the company's plans or operations.
Ongoing: Changes in the regulatory environment that could impact the company's prospects.

ROIX的主要风险是什么？

Potential: Lack of liquidity in the OTC market.
Potential: Limited or no financial disclosure.
Potential: High price volatility.
Ongoing: The company has no significant operations.
Ongoing: Uncertainty regarding the company's future plans.

ROIX的核心优势是什么？

Historical presence in cancer management.
Established network of IMPACT Centers (prior to liquidation).
Experience in pharmaceutical compounding.
Conducted outcomes research.

ROIX的劣势是什么？

No significant operations as of 2026.
Liquidated substantially all operating assets in 2002.
Lack of current revenue streams.
Limited market presence.

ROIX有哪些机遇？

Potential for restructuring and re-entry into the healthcare market.
Leveraging historical expertise in oncology care.
Exploring opportunities in healthcare technology.
Acquiring or merging with another healthcare company.

ROIX面临哪些威胁？

Competition from established healthcare providers.
Evolving regulatory landscape in the healthcare industry.
Difficulty in securing funding for new ventures.
Risk of obsolescence due to technological advancements.

ROIX的竞争对手是谁？

Genesis Healthcare, Inc. — Focuses on providing long-term care and rehabilitation services. — (GNRS)
LHC Group Inc — Provides in-home healthcare services. — (LHRP)
Quorum Health Corporation — Operates and manages general acute care hospitals and outpatient services. — (QMED)
RF Capital Group Inc. — Financial services company. — (RFCS)
Syneos Health Inc. — Provides biopharmaceutical acceleration services. — (SYNI)

Key Metrics

MoonshotScore: 46/100

Company Profile

CEO: Charles E. Sweet
Employees: 10
Founded: 2000

AI Insight

AI analysis pending for ROIX

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Response Oncology, Inc. do?

Response Oncology, Inc. formerly operated as a comprehensive cancer management company, providing advanced cancer treatment services, managing oncology practices, and compounding pharmaceuticals. However, the company liquidated substantially all of its operating assets in 2002 and currently has no significant operations. Any future business activities would depend on a complete restructuring and a new business plan.

What do analysts say about ROIX stock?

There is no current analyst coverage for ROIX stock due to the company's lack of significant operations and its listing on the OTC Other tier. The stock's behavior may not align with typical market dynamics, and traditional valuation metrics may not be applicable. Potential investors should conduct their own due diligence and carefully consider the risks associated with investing in this stock.

What are the main risks for ROIX?

The main risks for ROIX include the company's lack of significant operations, limited or no financial disclosure, high price volatility, and illiquidity in the OTC market. There is also uncertainty regarding the company's future plans and the potential for fraud or manipulation. Investors should be aware of these risks and conduct thorough due diligence before considering an investment in ROIX.